title: Voiding urosonography with ultrasound contrast agents for the diagnosis of vesicoureteric reflux in children. I. Procedure.
abstract: Voiding urosonography (VUS) encompasses examination of the urinary tract with intravesical administration of US contrast agent (UCA) for diagnosis of vesicoureteric reflux (VUR). The real breakthrough for US examination of VUR came with the availability of stabilized UCAs in the mid-1990s. This article presents a comprehensive review of various procedural aspects of VUS. Different US modalities are available for detecting the echogenic microbubbles: fundamental mode, colour Doppler US, harmonic imaging and dedicated contrast imaging with multiple display options. The reflux is graded (1 to 5) in a similar manner to the system used in voiding cystourethrography (VCUG). The most commonly used UCA for VUS, Levovist, is galactose-based and contains air-filled microbubbles. The recommended concentration is 300 mg/ml at a dose of 5-10%, or less than 5%, of the bladder filling volume when using fundamental or harmonic imaging modes, respectively. There are preliminary reports of VUS using a second-generation UCA, SonoVue. Here the UCA volume is less than 1% of the bladder filling volume. There is no specific contraindication to intravesical administration of UCA. The safety profile of intravesical Levovist is very high with no reports of side effects over a decade of use in VUS.
authors.affiliation: Department of Pediatric Radiology, University Hospital Wuerzburg, Josef-Schneider Strasse 2/D31, Wuerzburg, Germany. darge@roentgen.uni-wuerzburg.de
authors.forename: Kassa
authors.initials: K
authors.lastname: Darge
mesh_terms: D002648:Child; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D045423:Microbubbles; D010743:Phospholipids / Q000008:administration & dosage / Q000009:adverse effects; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects; D013459:Sulfur Hexafluoride / Q000008:administration & dosage / Q000009:adverse effects; D014463:Ultrasonography; D014718:Vesico-Ureteral Reflux / Q000000981:diagnostic imaging*
chemical_list: D003287:Contrast Media; D010743:Phospholipids; D011134:Polysaccharides; C420843:contrast agent BR1; C059891:SHU 508; D013459:Sulfur Hexafluoride